Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03067181 · ClinicalTrials.gov registry record · Phase 3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
A Phase 3 study of Germ Cell Tumor and Childhood Extracranial Germ Cell Tumor, sponsored by Children's Oncology Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,780
- Enrollment target
- 20
- Study locations
NCT03067181 is a Phase 3 study of Germ Cell Tumor and Childhood Extracranial Germ Cell Tumor that is actively recruiting participants, run by Children's Oncology Group. The registered enrollment target is 1,780 participants, above the 254-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (601% higher). The trial reports 20 study locations across 4 states.
The verdict
NCT03067181, a Phase 3 study of Germ Cell Tumor and Childhood Extracranial Germ Cell Tumor, is actively recruiting participants, sponsored by Children's Oncology Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,780 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors.
Conditions Studied
Interventions
- DRUG Carboplatin
- PROCEDURE Biospecimen Collection
- PROCEDURE Biopsy Procedure
- OTHER Best Practice
- BIOLOGICAL Bleomycin Sulfate
Study Locations (20)
Alaska
- Anchorage Associates in Radiation Medicine - Anchorage
- Anchorage Radiation Therapy Center - Anchorage
- Alaska Breast Care and Surgery LLC - Anchorage
- Alaska Oncology and Hematology LLC - Anchorage
- Alaska Women's Cancer Care - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
Arizona
- Kingman Regional Medical Center - Kingman
- Banner Children's at Desert - Mesa
- Cancer Center at Saint Joseph's - Phoenix
- Phoenix Childrens Hospital - Phoenix
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Arkansas
- CHI Saint Vincent Cancer Center Hot Springs - Hot Springs
- Arkansas Children's Hospital - Little Rock
- CARTI Cancer Center - Little Rock
- University of Arkansas for Medical Sciences - Little Rock
Alabama
- Children's Hospital of Alabama - Birmingham
- USA Health Strada Patient Care Center - Mobile
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,780 participants |
| Start Date | 2017-05-25 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03067181
The ClinicalTrials.gov registry entry for NCT03067181 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,780 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 254-participant average among 19 other Germ Cell Tumor trials with a reported enrollment target (601% higher). The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Germ Cell Tumor appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT03067181 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Alaska, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT03067181 about?
NCT03067181 is a clinical study titled "Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors". This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Chemotherapy drugs, such...
What is the current status of trial NCT03067181?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,780 participants. The study started on 2017-05-25. Estimated completion is 2027-06-30.
What conditions does trial NCT03067181 study?
This clinical trial studies the following conditions: Germ Cell Tumor, Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Malignant Germ Cell Tumor, Malignant Ovarian Teratoma.
What interventions are being tested in trial NCT03067181?
The interventions under investigation include: Carboplatin (DRUG), Biospecimen Collection (PROCEDURE), Biopsy Procedure (PROCEDURE), Best Practice (OTHER), Bleomycin Sulfate (BIOLOGICAL).
Who is sponsoring clinical trial NCT03067181?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03067181 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Germ Cell Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours
RECRUITING · Phase 3
-
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
ACTIVE NOT RECRUITING · Phase 3
-
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors
RECRUITING · Phase 1
-
Maintenance Oral Etoposide or Observation Following High-dose Chemo for GCT
RECRUITING · Phase 2
-
Germ Cell Tumor and Testicular Tumor DNA Registry
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.